Cargando…

1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada

BACKGROUND: In Canada, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed for the prevention of vaccine-type (VT) pneumonia in adults in July 2015. Herd effects stemming from the routine pediatric PCV13 program have historically led to reductions in VT disease in older adults, and there i...

Descripción completa

Detalles Bibliográficos
Autores principales: Vojicic, Jelena, Dion, Stephane, Isturiz, Raúl E, Laferriere, Craig, Major, Maria, Nepal, Rajeev M, Suaya, Jose A, McLaughlin, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252882/
http://dx.doi.org/10.1093/ofid/ofy210.1271
_version_ 1783373367463641088
author Vojicic, Jelena
Dion, Stephane
Isturiz, Raúl E
Laferriere, Craig
Major, Maria
Nepal, Rajeev M
Suaya, Jose A
McLaughlin, John M
author_facet Vojicic, Jelena
Dion, Stephane
Isturiz, Raúl E
Laferriere, Craig
Major, Maria
Nepal, Rajeev M
Suaya, Jose A
McLaughlin, John M
author_sort Vojicic, Jelena
collection PubMed
description BACKGROUND: In Canada, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed for the prevention of vaccine-type (VT) pneumonia in adults in July 2015. Herd effects stemming from the routine pediatric PCV13 program have historically led to reductions in VT disease in older adults, and there is currently no recommendation for a routine age-based PCV13 program for this age group. However, recent data suggest these indirect effects may have plateaued, leaving a persistent and substantial burden of potentially preventable pneumococcal disease in older adults. We evaluated the potential impact of PCV13 immunization program for Canadian adults aged ≥65 years on hospitalizations for community-acquired pneumonia (CAP). METHODS: We constructed a mathematical model based on Canada-specific burden of disease estimates and published estimates of PCV13 effectiveness and durability. We estimated the number of hospitalizations averted as the product of (i) the size of the Canadian population aged ≥65 years, (ii) the incidence of all-cause CAP, (iii) the proportion of CAP that is VT, (iv) PCV13 effectiveness, and (v) the duration of protection for PCV13 over a 5-year time horizon. We assumed that rates of all-cause CAP, the proportion of VT CAP, and PCV13 effectiveness remained constant over the 5-year assessment period. We assumed a 5% annual all-cause mortality rate in the overall population. We estimated hospital days averted as the product of hospitalizations averted and median length of stay. Model assumptions are summarized in Table 1. RESULTS: Based on model assumptions, PCV13 use in Canadian adults aged ≥65 years would lead to an annual rate reduction of 62 (11–77) hospitalizations per 100,000 persons, per year. This reduction, applied to the entire Canadian population of older adults, would avert an estimated 17,274 (3,037–21,711) hospitalizations and 138,192 (24,298–173,690) hospital days over a 5-year period. CONCLUSION: Despite herd effects from the routine pediatric program, direct PCV13 immunization of older adults in Canada could result in considerable additional reduction in hospitalizations for pneumonia. [Image: see text] DISCLOSURES: J. Vojicic, S. Dion, R. E. Isturiz, C. Laferriere, M. Major, R. M. Nepal, and J. A. Suaya: Pfizer: Employee and Shareholder, Benefits and stock and Salary; J. M. McLaughlin, Pfizer: Employee, Salary.
format Online
Article
Text
id pubmed-6252882
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62528822018-11-28 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada Vojicic, Jelena Dion, Stephane Isturiz, Raúl E Laferriere, Craig Major, Maria Nepal, Rajeev M Suaya, Jose A McLaughlin, John M Open Forum Infect Dis Abstracts BACKGROUND: In Canada, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed for the prevention of vaccine-type (VT) pneumonia in adults in July 2015. Herd effects stemming from the routine pediatric PCV13 program have historically led to reductions in VT disease in older adults, and there is currently no recommendation for a routine age-based PCV13 program for this age group. However, recent data suggest these indirect effects may have plateaued, leaving a persistent and substantial burden of potentially preventable pneumococcal disease in older adults. We evaluated the potential impact of PCV13 immunization program for Canadian adults aged ≥65 years on hospitalizations for community-acquired pneumonia (CAP). METHODS: We constructed a mathematical model based on Canada-specific burden of disease estimates and published estimates of PCV13 effectiveness and durability. We estimated the number of hospitalizations averted as the product of (i) the size of the Canadian population aged ≥65 years, (ii) the incidence of all-cause CAP, (iii) the proportion of CAP that is VT, (iv) PCV13 effectiveness, and (v) the duration of protection for PCV13 over a 5-year time horizon. We assumed that rates of all-cause CAP, the proportion of VT CAP, and PCV13 effectiveness remained constant over the 5-year assessment period. We assumed a 5% annual all-cause mortality rate in the overall population. We estimated hospital days averted as the product of hospitalizations averted and median length of stay. Model assumptions are summarized in Table 1. RESULTS: Based on model assumptions, PCV13 use in Canadian adults aged ≥65 years would lead to an annual rate reduction of 62 (11–77) hospitalizations per 100,000 persons, per year. This reduction, applied to the entire Canadian population of older adults, would avert an estimated 17,274 (3,037–21,711) hospitalizations and 138,192 (24,298–173,690) hospital days over a 5-year period. CONCLUSION: Despite herd effects from the routine pediatric program, direct PCV13 immunization of older adults in Canada could result in considerable additional reduction in hospitalizations for pneumonia. [Image: see text] DISCLOSURES: J. Vojicic, S. Dion, R. E. Isturiz, C. Laferriere, M. Major, R. M. Nepal, and J. A. Suaya: Pfizer: Employee and Shareholder, Benefits and stock and Salary; J. M. McLaughlin, Pfizer: Employee, Salary. Oxford University Press 2018-11-26 /pmc/articles/PMC6252882/ http://dx.doi.org/10.1093/ofid/ofy210.1271 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Vojicic, Jelena
Dion, Stephane
Isturiz, Raúl E
Laferriere, Craig
Major, Maria
Nepal, Rajeev M
Suaya, Jose A
McLaughlin, John M
1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title_full 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title_fullStr 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title_full_unstemmed 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title_short 1440. Potential Impact of Routine Use of 13-Valent Pneumococcal Conjugate Vaccine on Hospitalizations for Pneumonia among Older Adults in Canada
title_sort 1440. potential impact of routine use of 13-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among older adults in canada
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252882/
http://dx.doi.org/10.1093/ofid/ofy210.1271
work_keys_str_mv AT vojicicjelena 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT dionstephane 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT isturizraule 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT laferrierecraig 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT majormaria 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT nepalrajeevm 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT suayajosea 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada
AT mclaughlinjohnm 1440potentialimpactofroutineuseof13valentpneumococcalconjugatevaccineonhospitalizationsforpneumoniaamongolderadultsincanada